This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits for diabetic nephropathy, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for diabetic nephropathy. Key assets highlighted include Farxiga, Jardiance, Invokana, Kerendia, Ozempic, dapagliflozin + zibotenan, dapagliflozin + balcinrenone, empagliflozin + vicadrostat, and Mounjaro.  

This interview was conducted on 07 April 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.